Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2022-04-25 00:00:00 ET · period of report 2022-04-21 · accession 0000899243-22-015542 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-04-25 | 2022-04-21 | PYXS | Chin Mark | Former Dir | S - Sale | $3.05 | -1.75M | 0 | -100% | -$5.32M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-21 | S | D | 1,745,761 | $3.05 | 0 | I See footnote | — | — | (F1) The securities were held directly by Arix Bioscience Holdings Limited ("Arix"). The Reporting Person is one of for members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein. |